Merck signs up UK’s Avillion to develop psoriasis therapy
Merck has signed a collaboration agreement with the UK’s Avillion under which the latter will develop the German drug giant’s anti IL-17 A/F Nanobody as a treatment for plaque psoriasis.
Read More
